Elects Jane J. Song to the Board of Directors PLANO, Texas , March 25, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Anthony P. Bihl, III as Chairman of the Board of Directors, following Dr. Joseph A.
Record Fourth Quarter & Full Year 2018 Algovita® Sales of $14.1 million and $47.1 million, Up 36% and 84% YoY Respectively PLANO, Texas , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the
PLANO, Texas , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Fred Parks , PhD, Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the
PLANO, Texas , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2018 on Thursday, February 28, 2019 after market close.
Elects Christopher G. Chavez as a Member of the Board of Directors PLANO, Texas , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced the appointment of Fred B. Parks , PhD, as Chief Executive Officer, effective
PLANO, Texas , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a medical device company dedicated to neuromodulation, announced today that the U.S. Food and Drug Administration ( FDA ) has advised that its review of Company’s pre-market approval (PMA) application for its
PLANO, Texas , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018 . Preliminary unaudited consolidated revenue in the fourth
PLANO, Texas , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has entered into an agreement effective December 31, 2018 , to sell its wholly owned subsidiary NeuroNexus Technologies, Inc.
PLANO, Texas , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received full-body MR-conditional approval for the Company’s Algovita SCS system from its European Notified Body, TÜV SÜD.
PLANO, Texas , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita ® Spinal Cord Stimulation (SCS) system has been implanted in over 3,000 patients in the U.S.
PLANO, Texas , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has received U.S. Food and Drug Administration ( FDA ) head-only MR-conditional approval for the Company’s Algovita SCS system.
PLANO, Texas , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to participate in two
Reports Record Algovita ® Sales of $12.5 million , Up 98% YoY PLANO, Texas , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the third quarter ended September 30, 2018 .
PLANO, Texas , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2018 on Monday, October 29, 2018 after market close.
PLANO, Texas , Sept. 14, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $21.25 per share, which
PLANO, Texas , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 shares of its common stock at a price to the public of $21.25 per share.
PLANO, Texas , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it is commencing an underwritten follow-on public offering of its common stock. In addition, Nuvectra intends to grant the underwriters a 30-day
PLANO, Texas , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to participate in two
Reports Record Algovita® Sales of $11.5 million, Up 110% YoY PLANO, Texas , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended June 30, 2018 .
PLANO, Texas , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the appointment of Ben Tranchina as Chief Technology Officer (CTO), effective August 24, 2018 . Mr. Tranchina has over 25 years of industry experience and
PLANO, Texas , July 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2018 on Tuesday, August 7, 2018 after market close.
PLANO, Texas , July 10, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita® Spinal Cord Stimulation (SCS) system has been implanted in over 2,000 patients in the U.S.
PLANO, Texas , July 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today provided an update on its U.S. Food and Drug Administration ( FDA ) pre-market approval (PMA) application and its TÜV SÜD application for CE Mark in Europe for
PLANO, Texas , June 25, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it was added to the Russell 2000 ® Index when Russell Investments reconstituted its comprehensive set of U.S.
PLANO, Texas , May 17, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming
PLANO, Texas , May 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018 . Highlights Reported consolidated revenues of $10.6 million for the first quarter 2018,
PLANO, Texas , May 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018 . Highlights Reported consolidated revenues of $10.6 million for the first quarter 2018,
PLANO, Texas , April 23, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2018 on Wednesday, May 2, 2018 after market close.
Record Quarterly Algovita® Revenue of $10.4 Million PLANO, Texas , March 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the fourth quarter and full year ended December 31, 2017 .
PLANO, Texas , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming
PLANO, Texas , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2017 on Tuesday, March 6, 2018 after market close.
Agreement Provides Company with Increased Financial Flexibility and Extended Amortization Period PLANO, Texas , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with Silicon Valley Bank
PLANO, Texas , Feb. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $8.00 per share, which
PLANO, Texas , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the pricing of its underwritten follow-on public offering of 2,825,000 shares of its common stock at a price to the public of $8.00 per share.
PLANO, Texas , Jan. 31, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it is commencing an underwritten follow-on public offering of its common stock. In addition, Nuvectra intends to grant the underwriters a 30-day
PLANO, Texas , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2017 . Preliminary unaudited fourth quarter consolidated revenue is
Event to Feature Leading Physician Presentations on Nuvectra’s Algovita system PLANO, Texas , Jan. 03, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the company will host an Analyst & Investor Meeting on Friday, January
PLANO, Texas , Dec. 13, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the company’s Algovita ® Spinal Cord Stimulation (SCS) system has now been implanted in 1,000 patients across the U.S.
PLANO, Texas , Nov. 15, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th
PLANO, Texas , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to participate at the
Record Quarterly Algovita Revenues, Increasing to $6.3 Million PLANO, Texas , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the third quarter ended September 30, 2017 .
PLANO, Texas , Oct. 24, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2017 on Wednesday, November 1, 2017 after market close.
PLANO, Texas , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Noel Goldthwaite , MD, senior surgeon and founding member at SpineCare Medical Group, Inc. , is the first physician in northern California to implant Nuvectra’s Algovita ® Spinal Cord Stimulation System, which successfully treated a local injured
PLANO, Texas , Aug. 30, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & CFO, are scheduled to participate at the Morgan Stanley Global
Record Quarterly Algovita® Revenues, Increasing 62% Sequentially PLANO, Texas , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced financial results for the second quarter ended June 30, 2017 .
PLANO, Texas , July 28, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Wedbush
PLANO, Texas , July 25, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended June 30, 2017 on Tuesday, August 8, 2017 after market close.
PLANO, Texas , June 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration ( FDA ) for full-body MRI-conditional approval for the Company’s
PLANO, Texas , May 09, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2017 . Highlights Record total revenues of $5.0 million , including total Algovita sales of $3.4
PLANO, Texas , May 03, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 18th
PLANO, Texas , April 27, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended March 31, 2017 on Tuesday, May 9, 2017 after market close.
Investor event will feature Q&A on SCS market and Nuvectra’s Algovita system PLANO, Texas , March 27, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Cowen and Company and The Ruth Group are hosting a physician panel on
PLANO, Texas , March 07, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 30, 2016 . Recent Highlights Completed FDA Premarket Approval and TUV CE mark
PLANO, Texas , March 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 29th
PLANO, Texas , March 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen
PLANO, Texas , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter ended December 30, 2016 on Tuesday, March 7, 2017 before the market open.
PLANO, Texas , Feb. 14, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with the lenders of its $45 million credit facility, Silicon Valley Bank and Oxford Finance, to extend the availability of
PLANO, Texas , Feb. 06, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Operating Officer & Chief Financial Officer, are scheduled to conduct a fireside chat
PLANO, Texas , Feb. 01, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed regulatory submissions with the U.S. Food and Drug Administration ( FDA ) and CE Mark authorities for Virtis™, the Company’s sacral nerve
PLANO, Texas , Jan. 17, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, has recently been named recipient of the Frost & Sullivan North American New Product Innovation Award for its leadership in the spinal cord stimulation (SCS) market.
The intelligent and innovative Algovita® SCS System found strong favor among physicians and patients SANTA CLARA, Calif. , Jan. 5, 2017 /PRNewswire/ -- Based on its recent analysis of the spinal cord stimulation (SCS) market, Frost & Sullivan recognizes Nuvectra with the 2017 North American New
Nuvectra Signs Direct Supply Agreement with Minnetronix, Inc. for External Devices PLANO, Texas , Dec. 12, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced the completion of a direct supply agreement with Minnetronix, Inc.
PLANO, Texas , Nov. 21, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Financial Officer, are scheduled to present at the 28 th Annual Piper Jaffray
Continued Progress Building U.S. Sales Organization and Market Awareness of Algovita® System PLANO, Texas , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the third quarter ended September 30,
PLANO, Texas , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Financial Officer, are scheduled to present at the 7th Annual Craig-Hallum Alpha
PLANO, Texas , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the third quarter ended September 30, 2016 on Wednesday, November 9, 2016 after the market close.
Accelerating U.S. Sales Team Build and Initiated Algovita® Sales in the U.S. PLANO, Texas , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the second quarter ended July 1, 2016 .
PLANO, Texas , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today the formation of the Nuvectra Medical Advisory Board (“MAB”). The Nuvectra MAB is composed of three renowned experts in neurostimulation therapies and pain
PLANO, Texas , July 27, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended July 1, 2016 on Wednesday, August 10, 2016 after the market close.
PLANO, Texas , June 28, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has been added to the Russell Microcap ® Index. The addition occurred at the close of trading on June 24, 2016 when FTSE Russell reconstituted its
PLANO, Texas , May 11, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended April 1, 2016 . Recent Accomplishments & Highlights Completed spin-off from Greatbatch, Inc.
PLANO, Texas , April 26, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the first quarter ended April 1, 2016 , on Wednesday, May 11, 2016 after the market close.
PLANO, Texas , April 11, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees , Chief Executive Officer, and Walter Berger , Chief Financial Officer, are scheduled to present at the 15 th Annual Needham Healthcare
Nuvectra Announces Changes to Executive Management Team PLANO, Texas , April 07, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, today announced the appointment of Paul Hanchin in the newly created role of President, effective as of April 5,
Spin-off from Greatbatch creates new stand-alone neurostimulation company PLANO, Texas , March 14, 2016 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), formerly QIG Group, LLC , announced today the completion of its spin-off from Greatbatch, Inc.
Sets Record Date of March 7, 2016 and Nuvectra Share Distribution Date of March 14, 2016 FRISCO, Texas , Feb. 24, 2016 (GLOBE NEWSWIRE) -- Greatbatch, Inc. (NYSE:GB) today announced that its Board of Directors has approved the spin-off of QiG Group, LLC , which will convert into Nuvectra
Agreement Includes Strategic Investment in Aleva’s Current Series C Round by Greatbatch LAUSANNE , Switzerland , Feb. 01, 2016 (GLOBE NEWSWIRE) -- Aleva Neurotherapeutics, a leading company developing next-generation implants for deep brain stimulation (DBS) in major neurological indications
FRISCO, Texas, July 30, 2015 (GLOBE NEWSWIRE) -- Greatbatch, Inc. (NYSE: GB ) today announced it has filed a Form 10 registration statement with the U.S. Securities and Exchange Commission for its proposed tax-free spin-off of its neuromodulation subsidiary, QiG Group LLC, to be known post-spin as